Search by Drug Name or NDC
NDC 00069-5317-20 Paxlovid Details
Paxlovid
Paxlovid is a KIT in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is .
MedlinePlus Drug Summary
The combination of nirmatrelvir and ritonavir is used to treat coronavirus disease 2019 (COVID-19 infection) caused by the SARS-CoV-2 virus in adults who have mild to moderate symptoms and are at risk of severe disease that could result in hospitalization or death. The FDA has also issued an emergency use authorization (EUA) authorizing use of nirmatrelvir and ritonavir to treat coronavirus disease 2019 (COVID-19 infection) caused by the SARS-CoV-2 virus in children 12 years of age and older who weigh at least 88 pounds (40 kg). Nirmatrelvir is in a class of medications called antivirals. It works by stopping the virus from spreading in the body. Ritonavir is in a class of medications called pharmacokinetic boosters. It works by increasing the amount of nirmatrelvir available in the body so that the medication will have a greater effect.
Related Packages: 00069-5317-20Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Nirmatrelvir and Ritonavir
Ritonavir is used along with other medications to treat human immunodeficiency virus (HIV) infection. Ritonavir is in a class of medications called protease inhibitors. It works by decreasing the amount of HIV in the blood. Although ritonavir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting the HIV virus to other people.
Related Packages: 00069-5317-20Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Ritonavir
Product Information
| NDC | 00069-5317 |
|---|---|
| Product ID | 0069-5317_5d665f18-f17c-4fad-a42c-af817bb5373a |
| Associated GPIs | |
| GCN Sequence Number | 083290 |
| GCN Sequence Number Description | nirmatrelvir/ritonavir TAB DS PK 150-100 MG ORAL |
| HIC3 | W0M |
| HIC3 Description | ANTIVIRAL - MAIN PROTEASE (MPRO) INHIBITOR |
| GCN | 52199 |
| HICL Sequence Number | 047738 |
| HICL Sequence Number Description | NIRMATRELVIR/RITONAVIR |
| Brand/Generic | Brand |
| Proprietary Name | Paxlovid |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | nirmatrelvir and ritonavir |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | KIT |
| Route | n/a |
| Active Ingredient Strength | n/a |
| Active Ingredient Units | n/a |
| Substance Name | n/a |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA217188 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00069-5317-20 (00069531720)
| NDC Package Code | 0069-5317-20 |
|---|---|
| Billing NDC | 00069531720 |
| Package | 10 BLISTER PACK in 1 CARTON (0069-5317-20) / 1 KIT in 1 BLISTER PACK (0069-5317-02) * 1 TABLET, FILM COATED in 1 BLISTER PACK (0069-2085-11) * 1 TABLET, FILM COATED in 1 BLISTER PACK (0069-1735-11) |
| Marketing Start Date | 2023-10-18 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 67.1941 |
| Pricing Unit | EA |
| Effective Date | 2024-02-21 |
| NDC Description | PAXLOVID 150-100 MG DOSE PACK (RENAL DOSE) |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |